Asuka Pharmaceutical announced on August 12, 2026, the disposal of 53,600 common shares at 2,259 yen per share, along with a partial revision of the executive compensation system and the introduction of long-term incentives.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4886","jir_company_name":"Asuka Pharmaceutical Holdings Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-07-13","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/4886-20260713-01.pdf","jir_short_summary":"Asuka Pharmaceutical announced on August 12, 2026, the disposal of 53,600 common shares at 2,259 yen per share, along with a partial revision of the executive compensation system and the introduction of long-term incentives.","jir_summary":"### Details and Purpose of Disposal\nAsuka Pharmaceutical resolved on August 12, 2026, to dispose of 53,600 common shares at 2,259 yen per share. This disposal is part of a long-term incentive granted to directors based on a restricted stock compensation plan, aimed at enhancing shareholder value and motivating executives. The funds obtained from the disposal are planned to be used for partial revision of the executive compensation system and to promote long-term shareholder value sharing.\n\n### Revision of Executive Compensation System and Long-Term Incentives\nAsuka Pharmaceutical has partially revised its restricted stock compensation plan for directors by introducing a new scheme that grants shares over a long period to designated directors. The revision aims to increase the linkage between compensation and performance, setting the restricted period up to 50 years to foster long-term corporate value enhancement. This approach seeks to strengthen directors\u2019 commitment to corporate value and promote value sharing with shareholders.","jir_financial_highlights":"Number of shares disposed: 53,600 shares (Unknown)\nDisposal price: 2,259 yen per share (Unknown)\nTotal disposal amount: 121,082,400 yen (Unknown)","jir_category":"","jir_hashtags":"#AsukaPharmaceutical, #IRTypeRelated, #JapanStocks","jir_key_figures":"Number of shares disposed: 53,600 shares\nDisposal price: 2,259 yen per share\nTotal disposal amount: 121,082,400 yen","jir_meta_title":"[Asuka Pharmaceutical] Share Buyback and Long-Term Incentive System | July 2026","jir_meta_description":"Asuka Pharmaceutical disposed of 53,600 shares in August 2026, announced revisions to executive compensation and the introduction of long-term incentives. The goal is to enhance shareholder value.","jir_og_title":"[Asuka Pharmaceutical] Share Buyback and Long-Term Incentives | July 2026","jir_og_description":"Asuka Pharmaceutical announced share disposal and revisions to the executive compensation system, aiming to promote long-term corporate value and value sharing with shareholders.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":17164,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"share_cancellation","footnotes":""},"sector":[],"importance":[],"class_list":["post-79920","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n